Regeneron Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| REGN.VI | 9995.HK | ROIV | 4593.T | RPRX | 214450.KQ | |
|---|---|---|---|---|---|---|
| Market cap | 74.28B | 37.47B | 27.05B | 36.32B | 36.84B | 2.65T |
| P/E (TTM) | 20.8 | 5.4 | — | 258.7 | 33.9 | — |
| Forward P/E | — | 42.4 | -21.8 | -9.5 | 11.0 | — |
| Price/book | 2.6 | 3.6 | 6.4 | 4.1 | 4.2 | — |
| Dividend yield | 0.45% | — | — | — | 1.51% | 1.40% |
| 1-year change | +44.37% | −18.32% | +103.09% | −41.91% | +68.66% | −53.19% |
| Today | +0.80% | −5.98% | +1.77% | −3.93% | +2.57% | −3.41% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All REGN.VI news ›Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Bump from TD Cowen
MarketBeat Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Bump from TD Cowen - TD Cowen raised Regeneron’s price target from $960 to $980 and maintained a “buy” rating, implying 21.76% upside from the reported $804.88…
Frank Rimerman Advisors LLC Acquires 876 Shares of Regeneron Pharmaceuticals, Inc. $REGN
The firm also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This…
Immunovant: Batoclimab 2.0 Bull Case Flawed By Mixed Data, Competitive Threats
Immunovant's IMVT-1402 aims to deliver best-in-class FcRn inhibition, but mixed data tempers confidence in its superiority. See why IMVT stock is a Hold. - Immunovant is rated Hold as IMVT-1402 advances through five potentially…
Antibody Fragments Market Set to Reach US$ 13.1 Billion by 2034 at 5.7% CAGR
Updated · Oct 21, 2026 New York, NY – Oct 21, 2026 – Global Antibody Fragments Market size is expected to be worth around US$ 13.1 Billion by 2034 from US$ 7.5 Billion in 2024, growing at a CAGR of 5.7% during the forecast period 2025 to…
Regeneron-backed Parabilis rises ahead of trial data for lead asset
Parabilis Medicines (PBLS) stock jumps as the company sets an Oct. 24 webcast to update data from a Phase 1/2 trial for lead asset zolucetide. Read more here. Parabilis Medicines (PBLS), a recently IPO’d biotech backed by Regeneron (REGN),…
Bionyra’s Long-Acting Anti-TL1A Antibody BYN-002 Shows Roughly 80-Day Half-Life in Phase 1
Interim phase 1 data presented at UEG Week 2026 showed Bionyra Pharma’s Fc-engineered anti-TL1A antibody BYN-002 suppressed soluble TL1A with a half-life supporting potential every-3-to-6-month maintenance dosing in IBD. “TL1A has emerged…
Geron Lawsuit Ruling: Court Allows Investor Claims Over Rytelo Sales Statements to Move Forward
A federal judge in California has denied the defendant’s motion to dismiss an investor lawsuit alleging that the company and certain executives made false or misleading statements about Rytelo’s commercial progress. The ruling means the…
How Much Upside Is Left In Regeneron Stock?
Regeneron Pharmaceuticals (REGN) stock returned 37.9% in the year to October 16, 2026. This easily outpaced the 16.2% gain for the S&P 500 and left investors looking at a higher price. The underlying business has grown faster lately, yet…
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY,…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com40
-
tradingview.com16
-
gurufocus.com14
-
seekingalpha.com14
-
marketbeat.com12
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.